drugset / Trial / NCT00378456

Vitamins and Minerals for Children With Downs Syndrome

NCT00378456 ↗

RandomizedParallel-groupDouble-blind

Summary

The trial aimed to examine the effects of supplementation with antioxidants and folinic acid on the health, growth and psychomotor development of children with Down syndrome. 156 children with Trisomy 21, less than 7 months of age were recruited and randomised into four groups to receive antioxidants, folinic acid, a combination of antioxidants and folinic acid or a placebo. Blinded outcome assessment was carried out 18 months later.Blood and urine samples were also taken around 12 months of age to examine metabolic effects of supplementation.

Timeline

Start
—
Primary completion
—
Completion
—

Outcome

Missed primary endpoint

paper Children randomised to antioxidant supplements attained similar developmental outcomes to those without antioxidants PMID 18296460 ↗

paper Comparison of children randomised to folinic acid supplements or no folinic acid also showed no significant differences in Griffiths developmental quotient PMID 18296460 ↗

paper This study provides no evidence to support the use of antioxidant or folinic acid supplements in children with Down's syndrome. PMID 18296460 ↗

Drugs

EvaluationDrugModalityDoseRoute
Subject Leucovorin Small molecule 0.1 mg Oral
Subject Selenium Other / unclassified 10 ug Oral
Subject Vitamin A Unknown 0.9 mg Oral
Subject Vitamin C Other / unclassified 50 mg Oral
Subject Vitamin E Other / unclassified 100 mg Oral
Subject Zinc Sulfate Unknown 5 mg Oral

Indications